Can We Trust the FDA? Marty Makary on Science, Power & Patients

Key Takeaways

FDA Commissioner Makary is enacting reforms to rebuild public trust and accelerate medical advancements.
The FDA aims to streamline drug approvals by reducing trials, animal testing, and leveraging AI.
New FDA food guidance emphasizes protein while warning against refined carbohydrates.
The U.S. vaccine schedule is under review, proposing a core list of essential childhood vaccines.
Efforts are underway to lower drug prices and increase access to over-the-counter medications.

In 10 months, the FDA enacted 42 major reforms, including making rejection letters public for accountability.
Reforms target removing artificial food dyes and speeding up drug approval timelines from 10-12 years.
The agency is hiring 1,050 new scientists to support ambitious goals for accelerated drug approval pathways.

The FDA is reducing pivotal clinical trials from two to one, projected to save companies $100-300 million and shorten timelines.
Animal testing requirements are being reduced, specifically eliminating chimpanzee studies for monoclonal antibodies, previously using around 144 chimpanzees per drug.
A new pilot program aims to accelerate drug approval decisions to as few as 55 days for drugs addressing unmet public health needs, U.S. manufacturing, or affordability.
Companies can receive a voucher for expedited review if their drug meets specific criteria, such as addressing a national priority or lowering drug prices.

The FDA is streamlining regulations for cell and gene therapies to accelerate drug approvals.
Manufacturing requirements are being customized based on the drug and patient population, moving away from rigid, costly standards.
This aims to enable faster access to potentially life-saving treatments for rare diseases.
Concerns remain about potential outsourcing of CAR T therapy manufacturing to countries like China, which the FDA has moved to shut down.

The FDA's updated food pyramid corrects decades of scientifically inaccurate guidance influenced by industry, which focused on saturated fat while ignoring refined carbohydrates.
Previous guidance contributed to an obesity and pre-diabetes epidemic in children by promoting mass-produced refined carbohydrates.
New guidance emphasizes protein intake and warns against overconsumption of refined carbohydrates, which function like sugar.
Discussion highlighted the importance of soil quality, farming practices, and including more vegetarian protein options like nuts and beans.

Concerns were raised regarding U.S. competitiveness with China in biotechnology and the funding of scientific research.
NIH funding is proposed for reallocation from traditional treatments to research on root causes of diseases, such as food quality, sleep, and environmental exposures.
Critique was made of NIH's traditional focus on genetics, advocating for more research into environmental factors and lifestyle choices contributing to diseases.
Approximately 14% of NIH grants, amounting to about $40 billion annually, were directed towards Diversity, Equity, and Inclusion (DEI) research.

A review of the U.S. vaccine schedule under President Trump found it to be an international outlier, recommending 72 doses by age 18.
A comparison with 20 other developed countries revealed the U.S. recommends a significantly higher number of vaccine doses for children.
A list of approximately 38 core essential vaccines from age 0 to 18 was proposed to rebuild public trust and potentially increase vaccination rates.
Paternalism in medicine has damaged public trust, contributing to decreased childhood vaccinations and distrust in health authorities.

Drug costs in the United States consume 15% of GDP and are significantly more expensive than in other developed nations.
Reforms aim to accelerate biosimilar approvals, reducing R&D costs by over $100 million and shortening timelines from 5-8 years to 2.5 years.
The Trump administration's 'most favored nation status pricing' initiative aims to lower drug costs, citing a GLP-1 drug potentially priced at $149 for three months.
Transitioning more medications to non-prescription (over-the-counter) status is a major priority for 2026 to increase price transparency and reduce healthcare costs.

The FDA is developing guidance for AI decision support and wearables in healthcare diagnostics.
A clear consumer lane is being created, distinguishing between general consumer information and regulated medical applications.
Wearables providing physiological data will be deregulated, but claims of medical-grade accuracy will require FDA validation.
The FDA aims to provide predictability for developers and investors in this rapidly evolving market.

Autism diagnoses are increasing, with one in 12 boys in California currently diagnosed, a significant concern compared to previous generations.
Hypotheses suggest a potential autoimmune phenomenon where antibodies block folate receptors, hindering neural development, with Lukavorin discussed as a treatment.
The role of the microbiome in brain health is examined, noting gut bacteria produce a significant amount of the body's serotonin.
Factors like C-sections, infant formula, and antibiotic overuse are identified as detrimental to the microbiome, potentially leading to inflammation and discomfort.